Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis

Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis

Source: 
Pharmaceutical Business Review
snippet: 

Gilead Sciences announced that its GS-9674 has showed significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC) in a phase 2 trial.